Skip to content

Neogen NEOG Additional Paid-In Capital

Additional Paid-In Capital at other companies

Idexx Laboratories logo
Idexx LaboratoriesIDXX
$1.86B+9.8%
Zoetis logo
ZoetisZTS
$1.11B-6.4%
Revvity logo
RevvityRVTY
$1.24B-36.7%
Agilent Technologies logo
Agilent TechnologiesA
$5.63B+2.3%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$490.5M+3.1%
NeoGenomics logo
NeoGenomicsNEO
$1.28B+3.2%

Other financials

Income statement

See full
Revenue$211.2M-4.4%
Gross profit$99.0M-10.2%
Operating income-$3.3M-161%
Net income-$17.0M-56.0%
EPS (diluted)-$0.08-60.0%

Balance sheet

See full
Cash & equivalents$159.9M+25.2%
Total debt$793.3M-11.2%
Total equity$2.1B-21.0%
Total assets$3.4B-16.8%

Cash flow

See full
Operating cash flow$22.7M+16.7%
CapEx$11.6M-64.7%
Free cash flow$11.1M+182%

Valuation

See full
Market cap$2B+93.1%
Enterprise value$2.63B+45.5%
P/S2.3×+1.1×

Profitability

See full
Gross margin45.2%-3.6pp
Operating margin-73.1%+77.7pp
Net margin-69.9%+30.8pp
FCF margin-14%

Returns & leverage

See full
Return on equity-25.6%+28.8pp
Debt / equity0.4×0.0×
Current ratio3.9×0.0×

Where this comes from

Reported directly by Neogen in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Neogen’s 10-Q, filed April 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neogen's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neogen's additional paid-in capital?
Neogen (NEOG) reported additional paid-in capital of $2.61B in Q4 2025.
How has Neogen's additional paid-in capital changed year-over-year?
Neogen's additional paid-in capital increased by 0.6% year-over-year, from $2.6B to $2.61B.
What is the long-term trend for Neogen's additional paid-in capital?
Over 4 years (2021 to 2025), Neogen's additional paid-in capital has grown at a 72.3% compound annual growth rate (CAGR), from $294.95M to $2.6B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.